Your browser doesn't support javascript.
loading
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia.
Bloehdorn, Johannes; Braun, Andrejs; Taylor-Weiner, Amaro; Jebaraj, Billy Michael Chelliah; Robrecht, Sandra; Krzykalla, Julia; Pan, Heng; Giza, Adam; Akylzhanova, Gulnara; Holzmann, Karlheinz; Scheffold, Annika; Johnston, Harvey E; Yeh, Ru-Fang; Klymenko, Tetyana; Tausch, Eugen; Eichhorst, Barbara; Bullinger, Lars; Fischer, Kirsten; Weisser, Martin; Robak, Tadeusz; Schneider, Christof; Gribben, John; Dahal, Lekh N; Carter, Mathew J; Elemento, Olivier; Landau, Dan A; Neuberg, Donna S; Cragg, Mark S; Benner, Axel; Hallek, Michael; Wu, Catherine J; Döhner, Hartmut; Stilgenbauer, Stephan; Mertens, Daniel.
Afiliação
  • Bloehdorn J; Department of Internal Medicine III, University of Ulm, Ulm, Germany. johannes.bloehdorn@gmail.com.
  • Braun A; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Taylor-Weiner A; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Jebaraj BMC; Department of Internal Medicine III, University of Ulm, Ulm, Germany.
  • Robrecht S; Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany.
  • Krzykalla J; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
  • Pan H; Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Giza A; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
  • Akylzhanova G; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.
  • Holzmann K; Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany.
  • Scheffold A; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Johnston HE; Genomics Core Facility, Ulm University, Ulm, Germany.
  • Yeh RF; Department of Internal Medicine III, University of Ulm, Ulm, Germany.
  • Klymenko T; Centre for Cancer Immunology, Cancer Sciences, Faculty of Medicine, Cancer Research UK Centre and Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK.
  • Tausch E; Biostatistics, Genentech Inc., South San Francisco, CA, USA.
  • Eichhorst B; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Bullinger L; Department of Internal Medicine III, University of Ulm, Ulm, Germany.
  • Fischer K; Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany.
  • Weisser M; Medical Clinic for Hematology, Oncology and Tumor Biology, Charité University Hospital, Berlin, Germany.
  • Robak T; Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany.
  • Schneider C; Roche Pharma Research and Early Development, Penzberg, Germany.
  • Gribben J; Department of Hematology, Medical University of Lodz, Lodz, Poland.
  • Dahal LN; Department of Internal Medicine III, University of Ulm, Ulm, Germany.
  • Carter MJ; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Elemento O; Centre for Cancer Immunology, Cancer Sciences, Faculty of Medicine, Cancer Research UK Centre and Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK.
  • Landau DA; Department of Pharmacology and Therapeutics, Faculty of Life and Health Sciences, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
  • Neuberg DS; Centre for Cancer Immunology, Cancer Sciences, Faculty of Medicine, Cancer Research UK Centre and Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK.
  • Cragg MS; Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Benner A; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
  • Hallek M; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.
  • Wu CJ; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
  • Döhner H; Cancer Genomics and Evolutionary Dynamics, Weill Cornell Medicine, New York, NY, USA.
  • Stilgenbauer S; New York Genome Center, New York, NY, USA.
  • Mertens D; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nat Commun ; 12(1): 5395, 2021 09 13.
Article em En | MEDLINE | ID: mdl-34518531
ABSTRACT
Knowledge of the genomic landscape of chronic lymphocytic leukemia (CLL) grows increasingly detailed, providing challenges in contextualizing the accumulated information. To define the underlying networks, we here perform a multi-platform molecular characterization. We identify major subgroups characterized by genomic instability (GI) or activation of epithelial-mesenchymal-transition (EMT)-like programs, which subdivide into non-inflammatory and inflammatory subtypes. GI CLL exhibit disruption of genome integrity, DNA-damage response and are associated with mutagenesis mediated through activation-induced cytidine deaminase or defective mismatch repair. TP53 wild-type and mutated/deleted cases constitute a transcriptionally uniform entity in GI CLL and show similarly poor progression-free survival at relapse. EMT-like CLL exhibit high genomic stability, reduced benefit from the addition of rituximab and EMT-like differentiation is inhibited by induction of DNA damage. This work extends the perspective on CLL biology and risk categories in TP53 wild-type CLL. Furthermore, molecular targets identified within each subgroup provide opportunities for new treatment approaches.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Regulação Leucêmica da Expressão Gênica / Perfilação da Expressão Gênica / Instabilidade Genômica / Redes Reguladoras de Genes / Transição Epitelial-Mesenquimal Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Regulação Leucêmica da Expressão Gênica / Perfilação da Expressão Gênica / Instabilidade Genômica / Redes Reguladoras de Genes / Transição Epitelial-Mesenquimal Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha